Cure8 research brief
Fecal calprotectin measured by a point‑of‑care CGICA assay showed high accuracy for identifying colorectal inflammation and IBD in patients with chronic diarrhea, which could help avoid some unnecessary colonoscopies when pretest probability is low.
This directly matters to people with chronic diarrhea and clinicians deciding who needs urgent colonoscopy versus noninvasive evaluation.
Patients with chronic diarrhea; clinicians who evaluate and triage lower GI symptoms; labs and researchers working on fecal biomarkers for IBD.
This multicenter prospective diagnostic study evaluated a colloidal gold immunochromatographic assay fecal calprotectin (CGICA‑FC) test in patients with chronic diarrhea who all underwent colonoscopy.
The study reports cutoff values and AUCs showing high accuracy for detecting colorectal inflammation and particularly inflammatory bowel disease (higher cutoffs and AUCs for IBD than for high‑risk adenomas).
The authors emphasize a high negative predictive value, suggesting the test could help triage patients and reduce unnecessary colonoscopies in low‑pretest‑probability groups. The study enrolled 556 patients with chronic diarrhea and 152 controls across 15 centers in China and registered on the Chinese Clinical Trial Registry (ChiCTR2300070117).
FC levels correlated positively with colorectal inflammation and alcohol use and negatively with BMI. This brief summarizes the article abstract from the Journal of Gastroenterology and Hepatology; Cure8 did not review full text beyond the provided abstract.
Findings are from a prospective multicenter study summarized in the article abstract; performance may differ by assay type, population prevalence, and clinical setting. The assay performed poorly for high‑risk adenomas, so it should not replace colonoscopy when neoplasia is suspected.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
After bowel resection, Crohn’s often returns quietly at the surgical join (anastomosis). Early, planned monitoring can detect inflammation before symptoms appear and help prevent symptomatic recurrence or repeat surgery.
The article explains how gut bacteria may contribute to IBD and summarizes common tests and treatments people are likely to encounter. It highlights emerging microbial therapies (probiotics and FMT) that some patients...
Self‑management programs delivered by nurses may help people with IBD improve daily functioning, confidence in managing their condition, and quality of life even when inflammation markers don’t change. That matters...
